Cognition Therapeutics Inc Net Assets
Cognition Therapeutics Inc net assets. Based on the latest financial reports, Cognition Therapeutics Inc (CGTX) has net assets worth $36.53 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($43.40 Million) and total liabilities ($6.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CGTX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $36.53 Million |
| % of Total Assets | 84.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.93 |
Net Assets of Cognition Therapeutics Inc (2019–2024)
Net assets of Cognition Therapeutics Inc from 2019 to 2024. This chart illustrates how Cognition Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Cognition Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Cognition Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Cognition Therapeutics Inc from 2019 to 2024. For live market cap and overall valuation, see Cognition Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $18.75 Million | -23.39% |
| 2023-12-31 | $24.47 Million | -39.19% |
| 2022-12-31 | $40.25 Million | -21.50% |
| 2021-12-31 | $51.27 Million | +175.20% |
| 2020-12-31 | $-68.18 Million | -16.71% |
| 2019-12-31 | $-58.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cognition Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11692100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Cognition Therapeutics Inc Net Assets Breakdown (December 2024)
Cognition Therapeutics Inc net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.00K | 0.32% |
| Other Components | $193.85 Million | 1033.87% |
| Total Equity | $18.75 Million | 100.00% |
Cognition Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Cognition Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Croda International PLC
LSE:CRDA
|
$61.75 Million |
|
Kredyt Inkaso SA
WAR:KRI
|
$61.76 Million |
|
Kyungdong Gas
KO:012320
|
$61.76 Million |
|
PUBLIC POLICY HO.COM 144A
F:PD7
|
$61.79 Million |
|
Scully Royalty Ltd
NYSE:SRL
|
$61.74 Million |
|
Gamma Nu Inc
KQ:192410
|
$61.72 Million |
|
360 Capital REIT
AU:TOT
|
$61.72 Million |
|
Thantawan Industry Public Company Limited
BK:THIP
|
$61.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cognition Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 24,474,000 to 18,750,000, a change of -5,724,000 (-23.4%).
- Net loss of 33,971,000 reduced equity.
- New share issuances of 24,350,000 increased equity.
- Other comprehensive income increased equity by 195,000.
- Other factors increased equity by 3,702,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.97 Million | -181.18% |
| Share Issuances | $24.35 Million | +129.87% |
| Other Comprehensive Income | $195.00K | +1.04% |
| Other Changes | $3.70 Million | +19.74% |
| Total Change | $- | -23.39% |
Book Value vs Market Value Analysis
This analysis compares Cognition Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-2.66 | $0.70 | x |
| 2020-12-31 | $-3.11 | $0.70 | x |
| 2021-12-31 | $2.31 | $0.70 | x |
| 2022-12-31 | $1.39 | $0.70 | x |
| 2023-12-31 | $0.82 | $0.70 | x |
| 2024-12-31 | $0.47 | $0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cognition Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -181.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.61x
- Recent ROE (-181.18%) is below the historical average (-51.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.11 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.25 Million |
| 2021 | -22.85% | 0.00% | 0.00x | 1.15x | $-16.84 Million |
| 2022 | 1.88% | 0.00% | 0.00x | 1.25x | $-3.27 Million |
| 2023 | -105.37% | 0.00% | 0.00x | 1.44x | $-28.24 Million |
| 2024 | -181.18% | 0.00% | 0.00x | 1.61x | $-35.85 Million |
Industry Comparison
This section compares Cognition Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cognition Therapeutics Inc (CGTX) | $36.53 Million | 0.00% | 0.19x | $61.75 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2… Read more